[{"id":"50256d67-544c-4776-a24e-e908ef6c0213","acronym":"","url":"https://clinicaltrials.gov/study/NCT03722420","created_at":"2021-01-18T18:14:38.106Z","updated_at":"2024-07-02T16:35:16.250Z","phase":"Phase 3","brief_title":"Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)","source_id_and_acronym":"NCT03722420","lead_sponsor":"Il-Yang Pharm. Co., Ltd.","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • Supect (radotinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 238","initiation":"Initiation: 12/28/2018","start_date":" 12/28/2018","primary_txt":" Primary completion: 03/03/2023","primary_completion_date":" 03/03/2023","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-03-06"},{"id":"4636855d-4520-4fb3-8d46-4ea923436ef3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03459534","created_at":"2021-01-18T17:03:15.689Z","updated_at":"2024-07-02T16:35:33.559Z","phase":"Phase 3","brief_title":"A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs","source_id_and_acronym":"NCT03459534","lead_sponsor":"Il-Yang Pharm. Co., Ltd.","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • Supect (radotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 173","initiation":"Initiation: 06/25/2018","start_date":" 06/25/2018","primary_txt":" Primary completion: 01/29/2025","primary_completion_date":" 01/29/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2023-10-13"}]